Online ISSN: 2515-8260

Study of biochemical and other parameters in patients treated with remdesivir vs. without the remdesivir in mildmoderate covid 19 patients

Main Article Content

Dr. Bheemesh Vangalapati, Dr. Sudarshan Reddy, Dr. Venkappa S Mantur, Dr. Avula Naveen, Dr. Arun Kumar

Abstract

Background: The ACTT-1 trial showed that the median time to recovery was 10 days in the remdesivir group compared to 15 days in the placebo group. However, remdesivir failed to provide a survival benefit. This study puts in an effort to find the difference in biochemical and other parameters in patients treated with remdesivir vs. without the remdesivir in mildmoderate covid 19 patients.

Article Details